Biocytogen

3 Decision Makers · 4 Verified Contacts & Email Format

📍 Daxing, Beijing, ChinaFinance & Banking🗓 Est. 2008👥 1001–5000 employees

About Biocytogen

Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.

Email Format

{first_name}.{last_name}@biocytogen.com — 50.0%

sarah.smith@biocytogen.com

{first_letter_first_name}{last_name}@biocytogen.com — 50.0%

ssmith@biocytogen.com

Leadership & Decision Makers

Contact details of 3 Biocytogen decision makers

Yuelei Shen

Founder, President and CEO
  • Work email

    y***n@biocytogen.com

Tianquan Jin

Vice President

Chaoshe Guo

Vice President Sales and Marketing

Team & Specialists

Contact details of 1 Biocytogen team members

James Jin

VP LinkedIn
  • Work email

    j*******n@biocytogen.com

General Emails

General company emails, e.g. customer support lines

    info@biocytogen.com

    General Inquiries

    huiinfo@biocytogen.com

    General Inquiries

    tjin@biocytogen.com

    Unclassified inbox

    pleasecontactbd-licensing@biocytogen.com

    Unclassified inbox

    d-licensing@biocytogen.com

    Unclassified inbox

Similar Companies like Biocytogen

BMO Capital Markets

capitalmarkets.bmo.com
Finance & Banking · Toronto, Ontario, Canada · Est. 1988 · 1001–5000 employees

HQ: Toronto, Ontario, Canada

Bain Capital

baincapital.com
Finance & Banking · Boston, MA · Est. 1984 · 1001–5000 employees · $500M–$1B

HQ: Boston, MA

Blackstone Group

blackstone.com
Finance & Banking · New York, NY · Est. 1985 · 251–500 employees

HQ: New York, NY

Finance & Banking · Toronto, Ontario, Canada · Est. 1987 · 251–500 employees

HQ: Toronto, Ontario, Canada

ThedaCare

thedacare.org
Finance & Banking · Appleton, WI · Est. 1994 · 5001–10000 employees · $100M-$250M

HQ: Appleton, WI

Explore similar firms in the Finance & Banking sector

Company Info

Last updated: 27/07/2025

781-587-3558

Daxing, Beijing, China

Employees: 1001-5000
Founded Date: Nov 2008
Company Type: For Profit
Stock Symbol: HKG:02315
Operating Status: Active
Last Funding Type: Post-IPO Equity
Phone Number: 781-587-3558
Last Investment Activity: Mar 25, 2024
Investments Activity: Mar 25, 2024 Feb 19, 2024 Jan 24, 2024

Our service is undergoing beta testing, and you can get all the information that is closed on this page for free by registering. You will not need to provide your credit/debit card details.